Krystal Biotech (KRYS) EBT (2016 - 2026)

Krystal Biotech has disclosed EBT across 11 years of filings, most recently posting $61.4 million for Q1 2026.

• EBT for Q1 2026 came in at $61.4 million, up 40.93% year-over-year; the trailing twelve-month figure through Mar 2026 was $207.3 million (up 50.21% YoY), and the FY2025 annual result was $189.5 million, up 98.7% from the prior year.
• EBT came in at $61.4 million for Q1 2026 at Krystal Biotech, up from $51.1 million in the prior quarter.
• In the past five years, EBT ranged from a high of $80.7 million in Q3 2023 to a low of -$50.0 million in Q1 2022.
• The 5-year median for EBT is $16.0 million (2024), against an average of $12.9 million.
• Across the five-year window, EBT sank 215.99% in 2022 and surged 4577.79% in 2025, its largest moves.
• Krystal Biotech's EBT stood at -$32.1 million in 2022, then jumped by 133.25% to $10.7 million in 2023, then soared by 356.13% to $48.6 million in 2024, then rose by 5.19% to $51.1 million in 2025, then rose by 20.17% to $61.4 million in 2026.
• The last three EBT figures came in at $61.4 million (Q1 2026), $51.1 million (Q4 2025), and $48.0 million (Q3 2025), per Business Quant data.